

PATENT COOPERATION TREATY


1 PM / BLD

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

PCT 03 JUN 2005

To:

DEPPENBROCK, Bonnie L.
GlaxoSmithKline
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709
ETATS-UNIS D'AMERIQUE



NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Rule 71.1)

Date of mailing
(day/month/year)

27.09.2004

Applicant's or agent's file reference
PU4976WO

IMPORTANT NOTIFICATION

International application No.
PCT/US 03/39618

International filing date (day/month/year)
12.12.2003

Priority date (day/month/year)
13.12.2002

Applicant
SMITHKLINE BEECHAM CORPORATION et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.
4. **REMINDER**

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

The applicant's attention is drawn to Article 33(5), which provides that the criteria of novelty, inventive step and industrial applicability described in Article 33(2) to (4) merely serve the purposes of international preliminary examination and that "any Contracting State may apply additional or different criteria for the purposes of deciding whether, in that State, the claimed inventions is patentable or not" (see also Article 27(5)). Such additional criteria may relate, for example, to exemptions from patentability, requirements for enabling disclosure, clarity and support for the claims.

Name and mailing address of the international
preliminary examining authority:



European Patent Office
D-80298 Munich
Tel. +49 89 2399 - 0 Tx: 523656 epmu d
Fax: +49 89 2399 - 4465

Authorized Officer

Hebert, W

Tel. +49 89 2399-2152





INTERNATIONAL PRELIMINARY EXAMINATION REPORT
(PCT Article 36 and Rule 70)

Applicant's or agent's file reference PU4976WO	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/PEA/416)	
International application No. PCT/US 03/39618	International filing date (day/month/year) 12.12.2003	Priority date (day/month/year) 13.12.2002
International Patent Classification (IPC) or both national classification and IPC C07D471/10		
Applicant SMITHKLINE BEECHAM CORPORATION et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 5 sheets, including this cover sheet.
- ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).
- These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the opinion
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand 17.06.2004	Date of completion of this report 27.09.2004
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized Officer Boletti-Cremers, K Telephone No. +49 89 2399-8541 

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/US 03/39618

I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17))*):

Description, Pages

1-85 as originally filed

Claims, Numbers

1-47 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
☐ the language of publication of the international application (under Rule 48.3(b)).
☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
☐ filed together with the international application in computer readable form.
☐ furnished subsequently to this Authority in written form.
☐ furnished subsequently to this Authority in computer readable form.
☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
☐ the claims, Nos.:
☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)).

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. **PCT/US 03/39618**

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application,

☒ claims Nos. 31-35,45-47

because:

☒ the said international application, or the said claims Nos. 31-35,45-47 relate to the following subject matter which does not require an international preliminary examination (specify):

see separate sheet

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

☐ no international search report has been established for the said claims Nos.

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the Standard.

☐ the computer readable form has not been furnished or does not comply with the Standard.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes: Claims	3-34,37-40,43-47
	No: Claims	1,2,35,36,41,42
Inventive step (IS)	Yes: Claims	
	No: Claims	1-47
Industrial applicability (IA)	Yes: Claims	1-30,36-44
	No: Claims	

2. Citations and explanations

see separate sheet

POINT III.

For the assessment of the presently worded claims 31 to 35 , 45 to 47, on the question whether they are industrially applicable, no unified criteria exist in the PCT. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognise as industrially applicable claims to the use of a compound in medical treatment, but will allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a new medical treatment.

POINT V.

The following documents , quoted in the I.S.R., have been considered as relevant for the examination of the present application . Their numbering will be adhered to for the rest of the procedure.

D1: WO-A-94/26735

D2: WO-A-02/074770 (EP-A-1378510)*.

For obvious linguistic reasons , present report shall be based upon the analysis of the content of the EP document instead of the WO document mentioned under D2, based on the principle that their contents must be identical.

1. Novelty.

1.1 Besides the compounds which are said in the ISR (compounds 9,10, 46-48 and 51 of (1)) to affect the novelty of claims 1,2, 35, 36, 41 and 42 , (1) discloses under claim 1 of (1) , a teaching of compounds which entirely overlaps with claim 1 on file. Since the teaching of those compounds of (1) (refer especially to page 2 and 3 of (1)) is also involved in some of the diseases mentioned under claim 35 and 41 , also those claims cannot be regarded as novel in their present formulation.

The Applicant is therefore invited to amend those claims unambiguously , when the application will enter the regional proceedings, in order to permit not only a clear acknowledgement of the novelty vis à vis the content of (1), but also in order to permit a further (and complete) search report at a later stage of the regional proceedings.

Indeed, the IPEA agrees with the motivation of the ISA and invites the Applicant to reformulate the subject matter so as to enable a further search in the future.

1.2 In view of the fact that the compounds disclosed in (2) merely differ from those on file by the absence of a "B" ring (which in (2) are either a phenyl or a pyrazole ring) as defined in present application, the claimed matter can be regarded as novel vis à vis the content of (2)

2. Inventiveness.

2.1 Provided the claimed matter could be restricted to the use of the claimed compounds to a medical therapy which would treat only viral or bacterial infections, the inventiveness of the claims vis à vis the content of (1) could be acknowledged, because those uses are not suggested in (1), whereas the various other diseases meant are also to be found in (1).

2.2 Since the compounds of (2) possess the same pharmacological profile as those of present application, the Applicant is invited to show either by argumentation or technical evidence at the entry into the regional proceedings, that the claimed compounds on file possess any advantage or surprising feature when they are compared with those of (2) in order to enable the acknowledgment of the inventiveness of the application with respect to the content of (2).

3. Formal Point.

3.1 (1) and (2) should be mentioned and briefly discussed in the description.